Cargando…

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

BACKGROUND: Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the treatment of metastatic or unresectable locally advanced recurrent squamous cell carcinoma of the anus (SCCA) after demonstrating improved efficacy (12-month PFS of 47%) in the Epitopes-HPV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Stefano, Buecher, Bruno, André, Thierry, Jary, Marine, Bidard, François-Clément, Ghiringhelli, François, François, Éric, Taieb, Julien, Smith, Denis, de la Fouchardière, Christelle, Desramé, Jérôme, Samalin, Emmanuelle, Parzy, Aurélie, Baba-Hamed, Nabil, Bouché, Olivier, Tougeron, David, Dahan, Laëtitia, El Hajbi, Farid, Jacquin, Marion, Rebucci-Peixoto, Magali, Spehner, Laurie, Vendrely, Véronique, Vernerey, Dewi, Borg, Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183720/ https://www.ncbi.nlm.nih.gov/pubmed/32334548 http://dx.doi.org/10.1186/s12885-020-06841-1

Ejemplares similares

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma
por: Kim, Stefano, et al.
Publicado: (2022)

The Comparison of mDCF and mFOLFOX-6 as First-Line Treatment in Metastatic Gastric Cancer
por: Acikgoz, Yusuf, et al.
Publicado: (2021)

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)
por: Kim, Stefano, et al.
Publicado: (2017)

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
por: Kim, Stefano, et al.
Publicado: (2023)

Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial
por: Ochenduszko, Sebastian, et al.
Publicado: (2015)

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma
por: Kim, Stefano, et al.
Publicado: (2020)

Anti-Telomerase CD4(+) Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials
por: Spehner, Laurie, et al.
Publicado: (2020)

"Displasia coxo femoral (DCF) en el perro" /
por: Ocaña de la Rosa, Delhy
Publicado: (2009)

An analytic model for Throughput Optimal Distributed Coordination Function (TO-DCF)
por: Fitzgerald, Emma, et al.
Publicado: (2017)

Dcf1 induces glioblastoma cells apoptosis by blocking autophagy
por: Luo, Guanghong, et al.
Publicado: (2021)

Proof-of-concept study of the efficacy of a microbiota-directed complementary food formulation (MDCF) for treating moderate acute malnutrition
por: Mostafa, Ishita, et al.
Publicado: (2020)

Dcf1 Deficiency Attenuates the Role of Activated Microglia During Neuroinflammation
por: Wang, Jiao, et al.
Publicado: (2018)

Successful treatment with DCF chemotherapy and radiotherapy for primary squamous cell carcinoma of the prostate
por: Atagi, Kaya, et al.
Publicado: (2021)

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
por: André, Thierry, et al.
Publicado: (2023)

Overexpression of DCF1 inhibits glioma through destruction of mitochondria and activation of apoptosis pathway
por: Xie, Yuqiong, et al.
Publicado: (2014)

Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer
por: Dong, Lei, et al.
Publicado: (2014)

Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma
por: GÜRLER, Fatih, et al.
Publicado: (2022)

Developing shelf-stable Microbiota Directed Complementary Food (MDCF) prototypes for malnourished children: study protocol for a randomized, single-blinded, clinical study
por: Mostafa, Ishita, et al.
Publicado: (2022)

DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility study
por: FENG, ZENG-LI, et al.
Publicado: (2015)

Comparison the Incidence and Severity of Side Effects Profile Of FOLFOX and DCF Regimens in Gastric Cancer Patients
por: Salehifar, Ebrahim, et al.
Publicado: (2019)

Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis
por: Yamaguchi, Takahisa, et al.
Publicado: (2023)

The efficacy and adverse reactions of DCF and FOLFOXs regimens for patients with advanced gastric cancer in China: a meta-analysis
por: Chen, Minxue, et al.
Publicado: (2020)

Modified DCF (Docetaxel, Cisplatin and 5-fluorouracil) chemotherapy is effective for the treatment of advanced rectal squamous cell carcinoma
por: Hervé, Laure, et al.
Publicado: (2022)

Synthesis and Evaluation of the Antioxidant Activity of Lipophilic Phenethyl Trifluoroacetate Esters by In Vitro ABTS, DPPH and in Cell-Culture DCF Assays
por: Bernini, Roberta, et al.
Publicado: (2018)

Velocity-Adaptive V2I Fair-Access Scheme Based on IEEE 802.11 DCF for Platooning Vehicles
por: Wu, Qiong, et al.
Publicado: (2018)

Pyrocatalysis—The DCF assay as a pH-robust tool to determine the oxidation capability of thermally excited pyroelectric powders
por: Raufeisen, Sascha, et al.
Publicado: (2020)

New Dihydroxytyrosyl Esters from Dicarboxylic Acids: Synthesis and Evaluation of the Antioxidant Activity In Vitro (ABTS) and in Cell-Cultures (DCF Assay)
por: Roma, Elia, et al.
Publicado: (2020)

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
por: Cohen, Romain, et al.
Publicado: (2020)

Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study
por: Tanaka, Yoshihiro, et al.
Publicado: (2010)

Docetaxel, Cisplatin and Fluorouracil (DCF) Regimen Compared with Non-Taxane-Containing Palliative Chemotherapy for Gastric Carcinoma: A Systematic Review and Meta-Analysis
por: Chen, Xiao-Long, et al.
Publicado: (2013)

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T(H)1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study
por: Rebucci-Peixoto, Magali, et al.
Publicado: (2022)

The effect of an elemental diet on oral mucositis of esophageal cancer patients treated with DCF chemotherapy: a multi-center prospective feasibility study (EPOC study)
por: Tanaka, Yoshihiro, et al.
Publicado: (2018)

Docetaxel+Cisplatin+5-FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma: A Single-center Retrospective Cohort Study
por: Umeki, Yusuke, et al.
Publicado: (2023)

A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma
por: Satake, Hironaga, et al.
Publicado: (2016)

Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy
por: Nara, Katsuhiko, et al.
Publicado: (2023)

Efficacy and safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as perioperative chemotherapy treatments for resectable gastric cancer patients; a report from the middle east
por: Farrokhi, Pegah, et al.
Publicado: (2022)

Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study
por: Jary, Marine, et al.
Publicado: (2022)

Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59
por: Evrard, Camille, et al.
Publicado: (2022)

Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial
por: Charton, Emilie, et al.
Publicado: (2019)

Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)
por: Tougeron, David, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mcf6hkc6hklo6e2b02ltu33v37